CRVS — Corvus Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $895.89m
- $680.66m
Corvus Pharmaceuticals Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Corvus Pharmaceuticals Provides Business Update And Reports First Quarter 2023 Financial Results
Corvus Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Corvus Pharmaceuticals Terminated Sales Agreements With Jefferies Llc Effective Immediately
Brief: Corvus Pharmaceuticals Posts Q4 Net Loss Of $0.21 Per Share
Corvus Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Corvus Pharmaceuticals Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Corvus Pharmaceuticals Does Not Hold Cash Deposits Or Securities At Silicon Valley Bank
Corvus Pharmaceuticals Inc expected to post a loss of 23 cents a share - Earnings Preview
Corvus Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Corvus Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
Corvus Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Corvus Pharmaceuticals To Report Q3 Results On Nov 3, 2022
Brief: Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval For Phase 1/1B Clinical Trial Of Mupadolimab In China
Brief: Corvus Pharmaceuticals Reports Qtrly Loss Per Share $0.18
Corvus Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Corvus Pharmaceuticals Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: Corvus Pharmaceuticals Appoints James Rosenbaum Senior Vice President Of Research
Brief: Corvus Pharmaceuticals Provides Program Updates At Research And Development Symposium